Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer’s Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Condition(s):Mild Cognitive Impairment Due to Alzheimer’s DiseaseLast Updated:September 16, 2019Terminated